Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.31 |
| ▸ | CTSA | P10619 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | AURKAIP1 | Q9NWT8 | 1/20 | 0.31 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.31 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3598990 | 0.89 | ALDH1A1 (0.34) | KMT2AKDM4EALDH1A1MEN1ACLY | |
| SCHEMBL4162423 | 0.88 | HDAC3 (0.39) | KMT2AKDM4EALDH1A1MEN1ACLY | |
| SCHEMBL3600549 | 0.83 | RORC (0.36) | HPGDPTGDR2CTSA | |
| SCHEMBL3922425 | 0.82 | HPGD (0.32) | HPGDPTGDR2CTSA | |
| SCHEMBL3598133 | 0.80 | STAT3 (0.37) | HPGDPTGDR2CTSA | |
| SCHEMBL3607836 | 0.77 | CNR1 (0.41) | KMT2AALDH1A1MEN1MAPTPTGDR2 | |
| SCHEMBL3605220 | 0.77 | PSEN1 (0.37) | KMT2AKDM4EMEN1MAPTGAA | |
| SCHEMBL3594052 | 0.77 | CNR1 (0.40) | KMT2AALDH1A1MEN1MAPTGAA | |
| SCHEMBL3601631 | 0.76 | L3MBTL1 (0.35) | PTGDR2 | |
| SCHEMBL3593248 | 0.76 | ADRA1D (0.37) | HPGDPTGDR2CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087432-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2010-04-08 | — | — | US | claimed |
| EP-1828172-B1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2009-11-25 | — | — | EP | claimed |
| EP-1828172-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | Novartis AG (CH) | 2007-09-05 | — | — | EP | claimed |
| WO-2006063763-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2006-06-22 | — | — | WO | claimed |
| EP-1828172-B1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| EP-1828172-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | Novartis AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063763-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087432-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | PRLHR, AVPR2, CRHR2 | KMT2A 2130/4885KDM4E 2754/4885ALDH1A1 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.